Practices that show potential to achieve desirable public health outcomes in a specific real-life setting and are in the process of generating evidence of effectiveness or may not yet be tested.

Early innovations in opioid use disorder treatment and harm reduction during the COVID-19 pandemic: a scoping review

Krawczyk, N., Fawole, A., Yang, J., Tofighi, B.

Release Date:

Peer Review Study

Organizational Change/ Development
Policy Change/ Development
Healthcare Access and Quality
Tools Included
Outside U.S.

Mitigation and Prevention

Based on a literature review, the article synthesizes strategies used to prevent interruption of care for persons with opioid use disorders (SUDs). The review included OUD treatment and harm reduction services in five continents and a range of settings from substance use treatment to street outreach programs. Innovative service modifications to adapt to COVID-19 circumstances primarily involved expanded use of telehealth services (e.g., telemedicine visits for buprenorphine, virtual individual or group therapy sessions, provision of donated or publicly available phones), increased take-home medication allowances for methadone and buprenorphine, expanded uptake of long-acting opioid medications (e.g. extended-release buprenorphine and naltrexone), home delivery of services (e.g. MOUD, naloxone and urine drug screening), outreach and makeshift services for delivering MOUD and naloxone, and provision of a safe supply of opioids.

Resource Details

Outcomes of Interest

Reduction of Health Disparities

Priority Population(s)

People With Substance Use Disorders

Setting(s) of Implementation

Geographic Area of Implementation

Implementation Period